Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Hepatocellular 2Breast Neoplasms 2Sarcoma 1Prostatic Neoplasms 1Oligodendroglioma 1Neoplasms 1Liver Neoplasms, Experimental 1Liver Neoplasms 1Hemangiosarcoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1Adenoma, Liver Cell 1

Interventions

Temozolomide 26Radiotherapy 10Bevacizumab 10Carboplatin 6Irinotecan 5pembrolizumab 4Radiation 4Nivolumab 4IL13-PE38 4temsirolimus 3Surgical Procedures, Operative 3Magnetic Resonance Spectroscopy 3Immunotherapy, Adoptive 3Erlotinib Hydrochloride 3Aminolevulinic Acid 3trametinib 2olaparib 2lutetium Lu 177 dotatate 2fludarabine 2dabrafenib 2cemiplimab 2abemaciclib 2Vorinostat 2Transurethral Resection of Bladder 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Imatinib Mesylate 2Flucytosine 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Glioma × carotuximab × Clear all
NCT01648348 2018-05-23

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1/2 Completed
116 enrolled 17 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡